Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
40.86
+0.72 (1.79%)
Jul 30, 2025, 2:09 PM - Market open
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Tarsus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $67.14, which forecasts a 64.32% increase in the stock price over the next year. The lowest target is $51 and the highest is $84.
Price Target: $67.14 (+64.32%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 27, 2025.
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +76.21% | May 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $46 → $51 | Hold | Maintains | $46 → $51 | +24.82% | May 5, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $78 → $84 | Strong Buy | Maintains | $78 → $84 | +105.58% | May 2, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $54 → $58 | Strong Buy | Maintains | $54 → $58 | +41.95% | Mar 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $75 → $78 | Strong Buy | Maintains | $75 → $78 | +90.90% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
407.88M
from 182.95M
Increased by 122.94%
Revenue Next Year
587.91M
from 407.88M
Increased by 44.14%
EPS This Year
-1.21
from -3.07
EPS Next Year
1.92
from -1.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 452.2M | 747.0M | 940.9M | ||
| Avg | 407.9M | 587.9M | 806.4M | ||
| Low | 352.1M | 416.4M | 658.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 147.2% | 83.1% | 60.0% | ||
| Avg | 122.9% | 44.1% | 37.2% | ||
| Low | 92.4% | 2.1% | 11.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.69 | 3.54 | 8.10 | ||
| Avg | -1.21 | 1.92 | 4.40 | ||
| Low | -1.62 | 1.13 | 0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 321.3% | ||
| Avg | - | - | 128.8% | ||
| Low | - | - | -61.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.